Studies
This area is currently being rebuilt by us. You will receive more information on the ongoing studies here shortly.
ALTAMIRA
This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with MCL. Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab (Barf et al., 2017; Wang et al., 2017).
Download protocol (2021-10-22)
GELTAMO IMCL-2015 - Recruitment stopped!
The IMCL-2015 is a phase II study that evaluates a tailored frontline treatment using ibrutinib in combination with rituximab (IR) in indolent clinical forms of MCL. In addition, a
minimal residual disease (MRD)–driven time-limited treatment is incorporated.
Download protocol (2020-09-16)
TRIANGLE - Recruitment stopped!
Randomized, three-arm, parallel-group, open label, international phase III trial comparing six alternating courses of R-CHOP/R-DHAP (one cycle every 21 days) followed by ASCT versus the combination with ibrutinib in induction and maintenance (2 years) or the experimental arm without ASCT.
Prospective Randomized Comparison of Myeloablative Radiochemotherapy followed by Blood Stem Cell Transplantation versus Maintenance with Interferon alpha.
Download recruitment (2020-12-28)
Download protocol (2019-11-19)
MCL R2 Elderly - Recruitment stopped!
Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma.
Download recruitment (2020-08-10)
Download protocol (2019-06-24)
MCL Younger - Recruitment stopped!
Efficacy of 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and autologous stem cell transplantation versus alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation.
Download recruitment (2011-10-22)
MCL Elderly / MCL autologous SCT - Recruitment stopped!
Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs. R-FC) for elderly patients with mantle cell lymphoma not suitable for stem cell transplantation.